SES
23.2.2021 08:52:12 CET | Business Wire | Press release
Four of the top five major cruise companies have entered into long-term strategic framework agreements, with the majority extending through 2026 and beyond, for services delivered over SES's next-generation O3b mPOWER communications system, SES announced today. These agreements will enable enhanced connectivity experiences onboard their current fleets as well as ships planned as part of their extensive new-build programmes, and result in a backlog of over EUR 220 million.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210222006011/en/
The advanced connectivity solutions delivered by SES will elevate guest connectivity to provide an ultimate digital immersive experience, enabling more wearable technologies and unlocking more personalised services. This reflects a major trend across the cruise industry and the priorities of leading cruise companies as they prepare to resume sailing. The latest contracts with SES Networks reinforce that SES is the clear market leader within the cruise connectivity segment, having secured significant market share of the cruise companies' mega new-build ship programmes. Dating back to 2019, SES has provided over 13 Gbps – or 2/3 of the total capacity delivered to the cruise industry.
O3b mPOWER is SES's global terabit-level scalable constellation that will operate in medium earth orbit (MEO) – or 8,000km away from earth. Based on the proven success of SES's current O3b system, the new system provides an unprecedented increase in flexibility and throughput and is capable of continuously delivering multiple gigabits per second to a single ship anywhere on earth during seasonal peaks and in areas of high density. O3b mPOWER’s advanced technical features, which include a “follow-the-ship” capability, allow for maximum efficiency in delivering the highest throughput available today wherever a ship is travelling. The new O3b mPOWER system provides the ideal combination of global coverage and low-latency, high-throughput performance for the cruise market, ensuring seamless immersive wi-fi and connectivity experiences.
With satellites scheduled to launch in late 2021 and service beginning in 2022, the high-performance connectivity delivered by O3b mPOWER will help the cruise industry to:
- Leverage a highly-resilient global network to deliver an always-on fibre-like connectivity experience
- Deliver seamless and secured access to cloud-based platforms and applications for shipboard productivity, passenger communications and entertainment
- Dynamically optimise the required bandwidth and increased connectivity to any ship wherever and whenever it may be
- Deliver fastest internet speeds at sea, resulting in truly immersive guest experiences
- Achieve cruise liners’ operational efficiencies by enabling real-time condition monitoring and other connected Operational Technology (OT)
“COVID-19 has been challenging for the cruise industry. At the same time, it has also enabled major players in the industry to re-strategise on their plans for the future and focus on technology-driven innovation and how they can outdo themselves in creating the best holiday experience for passengers, and high-performance connectivity is central to those strategies. We are pleased to be co-creating these advanced solutions along with our customers and ensuring we can meet their future needs,” said JP Hemingway, CEO of SES Networks.
Follow us on:
https://twitter.com/SES_Satellites
https://www.facebook.com/SES.Satellites
https://www.youtube.com/ses
https://www.linkedin.com/company/ses/
https://www.instagram.com/ses_satellites/
Read our Blogs >
Visit the Media Gallery >
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,200 channels and has an unparalleled reach of 367 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222006011/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom